

Jury Out on West Nile's Possible Role as a Teratogen

BY DOUG BRUNK
San Diego Bureau

TUCSON, ARIZ. — Recent published data suggest a risk of birth defects among live-born infants of mothers infected with West Nile virus, but much more work is needed to confirm the association, Dr. Dawn M. Wesson said at the annual meeting of the Teratology Society.

"There appears to be a slightly higher frequency of major birth defects in the West Nile-infected group as compared to the general population, but ... even though this is suggestive it's certainly not proof," cautioned Dr. Wesson, of the department of tropical medicine at Tulane University School of Public Health and Tropical Medicine in New Orleans.

She based her remarks on a clinical study of 77 women infected with West Nile virus (WNV) during pregnancy in 2003 and 2004 who were followed in 16 states. Of the 77 women, 71 delivered 72 live infants. Four women had miscarriages and two had abortions (*Pediatrics* 2006;117:e537-45).

Of the 72 live infants, 67 were born at term, 4 were born preterm, and the gestational age of 1 infant was unknown.

The researchers, led by Daniel R. O'Leary, D.V.M., of the division of vector-borne infectious diseases at the Centers for Disease Control and Prevention, found that nearly 11% of infants born to mothers infected with West Nile virus during pregnancy had major birth defects, compared with almost 6% of infants born to uninfected mothers in the general population.


The researchers cautioned that of the 72 infants followed to date, nearly all appeared to be normal, and none had conclusive laboratory evidence of congenital WNV infection. Seven infants had major malformations, but "only three had defects that could have been caused by maternal WNV infection based on the timing of the infections and the developmental period for the specific malformations, and none had any conclusive evidence of WNV etiology," Dr. O'Leary and his associates wrote.

At the meeting, Dr. Wesson said one of the key reasons researchers are unable to determine with certainty whether WNV is a teratogen is that the sensitivity and specificity of IgM testing of cord blood to detect WNV is really unknown. "Also, congenital WNV infection among newborns with IgM-negative serology cannot be ruled out," she said. "We need more studies."

In a partnership between the Centers for Disease Control and Prevention and Tulane University, researchers are studying the effect of WNV on pregnancy outcomes in two groups of women: retrospectively in those infected while pregnant during 2003 and 2004, and prospectively in those infected while pregnant between 2005 and 2008.

In addition to performing all recommended tests during and after pregnancy, the researchers plan to follow case and control infants with ophthalmologic and developmental exams as well as a CT scan if indicated, and a dysmorphology exam in infected infants.

The final part of the effort is to perform morphologic, endocrine, and molecular assessments of the villous placenta, trophoblast, conceptus membranes, and maternal decidua. "We don't know the answer to the question [about WNV's possible role as a teratogen], but I think the pieces that we have in place and the collaborators we have in line should help us to answer those questions," Dr. Wesson concluded. ■



The sensitivity and specificity of IgM testing of cord blood to detect WNV is really unknown. The virus is shown here by electron micrograph.

CDC



new

Introducing Levemir®:
a long-acting basal insulin
with a light touch

New Levemir: for your patients who need a safe and effective way to improve A1C control

With proven reductions in A1C and FPG levels over time, Levemir can help your patients get to goal with up to 24 hours of glycemic control. Patients with diabetes can experience a consistent blood glucose response from injection to injection. Less weight gain was observed with Levemir in 12 of 12 clinical trials.* And Levemir is available in the Levemir® FlexPen®. FlexPen is the world's #1 selling prefilled insulin pen.† So start your patients with diabetes on Levemir, and help them experience the light side of basal insulin.

Levemir is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information
Levemir should not be diluted or mixed with any other insulin preparations. Levemir is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin dose should be made cautiously

and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Levemir is not to be used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir from other intermediate or long-acting insulin preparations. The dose of Levemir may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients

in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir and NPH insulin is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.



new Levemir®

insulin detemir (rDNA origin) injection

Lighter years ahead



Reference: 1. IMS Health, IMS MIDAS [12 months ending September 2005]. Please see brief summary of Prescribing Information on adjacent page. FlexPen and Levemir are registered trademarks of Novo Nordisk A/S.

© 2006 Novo Nordisk Inc. 130299R1 May 2006